GT Biopharma Inc

Research GT Biopharma Inc (GTBP) on Bullrun: market cap USD 15.87M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerGTBP
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 15.87M
• Financial periodFY2025
• Net income-USD 28.35M

Valuation Snapshot

latest market cap is USD 15.87M.

About GT Biopharma Inc

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid;

Frequently asked questions

What is GT Biopharma Inc's market cap?

GT Biopharma Inc's market capitalization is USD 15.87M.

What does GT Biopharma Inc do?

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms.